Search

Relay Therapeutics Inc

Fermé

SecteurSoins de santé

18.1 0.17

Résumé

Variation du prix de l'action

24h

Actuel

Min

18.02

Max

18.2

Chiffres clés

By Trading Economics

Revenu

2M

-82M

BPA

-0.37

Marge bénéficiaire

-23,916.286

Employés

218

EBITDA

1.9M

-81M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+60.31% upside

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

719M

4.5B

Ouverture précédente

17.93

Clôture précédente

18.1

Relay Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 nov. 2026, 21:07 UTC

Relay Therapeutics, Inc. shares are rising, supported by gains in the Biotechnology sub-sector, despite earlier pulling back from a session high amid volatility.

12 nov. 2026, 22:11 UTC

Relay Therapeutics, Inc. finished lower in after-market trading, continuing a trend of declines and remaining below its 20-day moving average.

10 nov. 2026, 21:07 UTC

Relay Therapeutics, Inc. shares declined sharply, reversing from an early peak and finishing near session lows, reflecting a weaker performance since Monday's close.

9 nov. 2026, 21:03 UTC

Relay Therapeutics, Inc. shares are advancing sharply, trading with unusually high volume and well above its 20-day moving average.

6 nov. 2026, 21:02 UTC

News

Jones Trading analyst Boris Peaker raised the price target on Relay Therapeutics to $31.00 from $20.00 while maintaining a Buy rating.

5 nov. 2026, 21:04 UTC

Relay Therapeutics, Inc. shares are declining amid a broader market downturn, remaining under pressure and trading near the lower end of their one-month range.

4 nov. 2026, 22:02 UTC

News

Relay Therapeutics reported a net loss of $81.7 million, or $0.37 per share, for Q3 2026, better than the expected $0.40 loss.

3 nov. 2026, 20:46 UTC

Relay Therapeutics, Inc. is trading higher on Tuesday after reaching a peak earlier in the session, though it remains below its 20-day moving average.

2 nov. 2026, 21:04 UTC

Shares of Relay Therapeutics, Inc. fell sharply, reversing recent upward momentum amid a broader decline in the market.

30 oct. 2026, 20:03 UTC

Relay Therapeutics, Inc. shares fell sharply after briefly rising earlier in the session.

29 oct. 2026, 20:07 UTC

Shares of Relay Therapeutics, Inc. declined, pulling back from an earlier session high, as part of a broader market trend closing lower.

28 oct. 2026, 23:36 UTC

News

Relay Therapeutics will report its Q3 2026 financial results on November 4, 2026, after the market close, amid ongoing development of zovegalisib.

27 oct. 2026, 20:31 UTC

Relay Therapeutics, Inc. is seeing modest gains in after-market trading, rising from a low shortly after the market closed and trading above its 20-day moving average.

26 oct. 2026, 19:46 UTC

Relay Therapeutics Inc shares are declining, continuing a downward trend observed over the last three sessions, despite a brief peak earlier in the session.

23 oct. 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining amid a broader market downturn, despite an earlier rebound from a session low.

22 oct. 2026, 19:56 UTC

Social Media

Relay Therapeutics Inc shares are modestly lower, having retraced from an early gain and currently positioned around the midpoint of its one-month trading range.

21 oct. 2026, 19:36 UTC

Relay Therapeutics Inc shares are declining, pulling back from an earlier peak, and are modestly lower since Tuesday's close amid session volatility.

20 oct. 2026, 20:01 UTC

Relay Therapeutics Inc shares are advancing sharply, continuing an upward trend with a notable increase since Monday's close, reaching a peak before the close.

19 oct. 2026, 19:46 UTC

Relay Therapeutics Inc shares are sharply higher.

16 oct. 2026, 20:02 UTC

Relay Therapeutics Inc shares are declining, reversing a trend of higher daily closes observed in recent sessions, reflecting a shift in momentum.

15 oct. 2026, 19:46 UTC

Relay Therapeutics Inc is trading higher, having reached a peak return during Thursday's session.

14 oct. 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, positioned near the lower end of their one-month range and below the 20-day moving average.

13 oct. 2026, 20:07 UTC

Relay Therapeutics Inc shares are declining, following significant volatility and a drop to their lowest point mid-session, trading well below the 20-day moving average.

12 oct. 2026, 22:02 UTC

Relay Therapeutics Inc shares are trading modestly lower in after-market hours, continuing a decline amid broader weakness in the biotechnology sector.

9 oct. 2026, 20:06 UTC

Relay Therapeutics Inc shares are advancing, continuing a recovery trend after prior declines, despite earlier pulling back from a notable peak in today's session.

8 oct. 2026, 23:01 UTC

Relay Therapeutics Inc shares are sharply lower in after-market trading, continuing a trend of declines following four consecutive lower daily closes.

7 oct. 2026, 19:35 UTC

Relay Therapeutics Inc shares fell sharply, reaching their lowest point around mid-day, despite a brief rebound earlier in the session.

6 oct. 2026, 20:00 UTC

Relay Therapeutics Inc shares fell sharply, breaking a trend of higher daily closes amid unusually high volume and a broader downturn in the biotechnology sector.

5 oct. 2026, 19:16 UTC

Relay Therapeutics Inc is gaining, recovering from an earlier low and continuing an upward trend after three consecutive sessions of positive performance.

2 oct. 2026, 21:01 UTC

Relay Therapeutics Inc declined during after-market hours, moving lower from Friday's close after initially starting with a slight gain.

Comparaison

Variation de prix

Relay Therapeutics Inc prévision

Objectif de Prix

By TipRanks

60.31% hausse

Prévisions sur 12 Mois

Moyen 29 USD  60.31%

Haut 31 USD

Bas 26 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

6

Achat

0

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat